Proton Beam Therapy with Concurrent Chemotherapy for Glioblastoma Multiforme: Comparison of Nimustine Hydrochloride and Temozolomide

Overview

Journal J Neurooncol

Publisher Springer

Date 2016 Aug 19

PMID 27535747

Citations 25

Authors

Masashi Mizumoto

Tetsuya Yamamoto

Eiichi Ishikawa

Masahide Matsuda

Shingo Takano

Hitoshi Ishikawa

Toshiyuki Okumura

Hideyuki Sakurai

Akira Matsumura

Koji Tsuboi

Affiliations

Soon will be listed here.

Abstract

To evaluate the safety and efficacy of postoperative proton beam therapy (PBT) combined with nimustine hydrochloride (ACNU) or temozolomide (TMZ) for glioblastoma multiforme (GBM). The subjects were 46 patients with GBM who were treated with high dose (96.6 GyE) PBT. There were 24 males and 22 females, and the median age was 58 years old (range 24-76). The Karnofsky performance status was 60, 70, 80, 90 and 100 in 5, 10, 12, 11 and 8 patients, respectively. Total resection, partial resection, and biopsy were performed for 31, 14 and 1 patients, respectively. Photon beams were delivered to high intensity areas on T2-weighted magnetic resonance imaging (MRI) in the morning (50.4 Gy in 28 fractions). More than 6 h later, PBT was delivered to the enhanced area plus a 10 mm margin in the first half of the protocol (23.1 GyE in 14 fractions) and to the enhanced volume in the second half (23.1 GyE in 14 fraction). Concurrent chemotherapy with ACNU during weeks 1 and 4 or daily TMZ was administered in 23 and 23 patients, respectively. The overall 1 and 2 year survival rates were 82.6 and 47.6 %, respectively. Median survival was 21.1 months (95 % CI 13.1-29.2), with no significant difference in survival between the ACNU and TMZ groups. The patient characteristics were similar in the two groups. Late radiation necrosis occurred in 11 patients (six ACNU, five TMZ), but was controlled by necrotomy and therapy including bevacizumab. PBT concurrent with ACNU or TMZ was tolerable and beneficial for carefully selected patients with GBM.

Citing Articles

Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis.

Valenzuela-Fuenzalida J, Moyano-Valarezo L, Silva-Bravo V, Milos-Brandenberg D, Orellana-Donoso M, Nova-Baeza P J Clin Med. 2024; 13(12).

PMID: 38929990 PMC: 11204640. DOI: 10.3390/jcm13123460.

Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.

Sadowski K, Jazdzewska A, Kozlowski J, Zacny A, Lorenc T, Olejarz W Int J Mol Sci. 2024; 25(11).

PMID: 38891962 PMC: 11172387. DOI: 10.3390/ijms25115774.

Analysis of person-hours required for proton beam therapy for pediatric tumors.

Mizumoto M, Fukushima H, Miyamoto T, Oshiro Y, Sumiya T, Iizumi T J Radiat Res. 2023; 64(3):599-601.

PMID: 37134315 PMC: 10214988. DOI: 10.1093/jrr/rrad022.

High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis.

Matsuda M, Mizumoto M, Kohzuki H, Sugii N, Sakurai H, Ishikawa E Radiat Oncol. 2023; 18(1):38.

PMID: 36823671 PMC: 9948305. DOI: 10.1186/s13014-023-02236-1.

Charged particle therapy for high-grade gliomas in adults: a systematic review.

Wang Y, Liu R, Zhang Q, Dong M, Wang D, Chen J Radiat Oncol. 2023; 18(1):29.

PMID: 36755321 PMC: 9906872. DOI: 10.1186/s13014-022-02187-z.

References

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

Bui Q, Lieber M, Withers H, Corson K, Van Rijnsoever M, Elsaleh H . The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects. Int J Radiat Oncol Biol Phys. 2004; 60(3):871-8. DOI: 10.1016/j.ijrobp.2004.04.019. View

Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D . Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23(10):2372-7. DOI: 10.1200/JCO.2005.00.331. View

Iuchi T, Hatano K, Uchino Y, Itami M, Hasegawa Y, Kawasaki K . Methionine Uptake and Required Radiation Dose to Control Glioblastoma. Int J Radiat Oncol Biol Phys. 2015; 93(1):133-40. DOI: 10.1016/j.ijrobp.2015.04.044. View

Mirimanoff R, Gorlia T, Mason W, van den Bent M, Kortmann R, Fisher B . Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006; 24(16):2563-9. DOI: 10.1200/JCO.2005.04.5963. View

Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-22. DOI: 10.1056/NEJMoa1308345. View

Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G . Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007; 356(15):1527-35. DOI: 10.1056/NEJMoa065901. View

Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K . Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2014; 88(4):793-800. DOI: 10.1016/j.ijrobp.2013.12.011. View

10.

Lubelski D, Abdullah K, Weil R, Marko N . Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. J Neurooncol. 2013; 115(3):317-22. DOI: 10.1007/s11060-013-1233-0. View

11.

Mizumoto M, Tsuboi K, Igaki H, Yamamoto T, Takano S, Oshiro Y . Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009; 77(1):98-105. DOI: 10.1016/j.ijrobp.2009.04.054. View

12.

Yonezawa S, Miwa K, Shinoda J, Nomura Y, Asano Y, Nakayama N . Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. J Neurooncol. 2014; 119(1):101-9. DOI: 10.1007/s11060-014-1453-y. View

13.

Stupp R, Dietrich P, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P . Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20(5):1375-82. DOI: 10.1200/JCO.2002.20.5.1375. View

14.

Matsuda M, Yamamoto T, Ishikawa E, Nakai K, Zaboronok A, Takano S . Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy. Br J Radiol. 2011; 84 Spec No 1:S54-60. PMC: 3473893. DOI: 10.1259/bjr/29022270. View

15.

Fitzek M, Thornton A, Rabinov J, Lev M, Pardo F, Munzenrider J . Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg. 1999; 91(2):251-60. DOI: 10.3171/jns.1999.91.2.0251. View

16.

Mizumoto M, Yamamoto T, Takano S, Ishikawa E, Matsumura A, Ishikawa H . Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy. Pract Radiat Oncol. 2014; 5(1):e9-16. DOI: 10.1016/j.prro.2014.03.012. View

17.

Stewart L . Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359(9311):1011-8. DOI: 10.1016/s0140-6736(02)08091-1. View

18.

Fine H, Dear K, Loeffler J, Black P, Canellos G . Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 71(8):2585-97. DOI: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s. View

19.

Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y . Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys. 2010; 82(1):83-9. DOI: 10.1016/j.ijrobp.2010.09.020. View

20.

Walker M, Strike T, SHELINE G . An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979; 5(10):1725-31. DOI: 10.1016/0360-3016(79)90553-4. View